Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck

Slide schematic 3/3

list 1/1 table 1/1 title 1/1

Components 3

bullet data headline

Tools 1

table/data: As of 6/20/2023 Shares of common stock outstanding 65.4 million Pre-funded warrants 28.9 million Merger consideration Shares of common 13.0 million Shares of preferred 0.4 million Preferred conversion ratio 1

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · slide 4